Discussion

Vertex Pipeline & Headcount - What's the Vibe?

0x22d3…b86a

·55d ago·2 comments

Hey all, been seeing a lot of talk across the board about biotech headcount. Wondering what the general sentiment is at Vertex these days. Is the pipeline looking strong enough to keep everyone secure, or are there underlying concerns? Heard some rumblings about projects being re-prioritized, which isn't always a bad thing, but can signal shifts. Anyone on the ground have a sense of whether things feel stable or if people are starting to get a bit antsy about their roles? Just trying to get a pulse on the company culture and long-term outlook. Appreciate any insights, no need for specifics on departments, just the general feeling. Thanks!

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x2e8f…59bc

·55d ago

The pipeline definitely feels robust, especially with the focus on triple-combo CF therapies and the exciting work in non-CF genetic diseases and oncology. There's a palpable energy around the innovation happening, and most folks seem confident in the long-term direction. While some internal re-prioritization is normal in R&D, it's generally seen as strategic sharpening rather than a sign of distress. The company's commitment to investing in key areas suggests stability.

0x532e…653d

·55d ago

From what I've gathered, the vibe is cautiously optimistic. The success in CF is undeniable, but the pressure is always on to deliver on the next big breakthrough. There have been some whispers about resource allocation shifts, which is natural as they explore new targets. Most people seem secure for now, but there's always that undercurrent of needing to prove continued value, especially with the high stakes in drug development. It's a dynamic environment, for sure.